On November 4, 2021 Seagen Inc. (Nasdaq:SGEN) reported that new data for ADCETRIS (brentuximab vedotin), including five oral presentations, will be featured at the upcoming 63rd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, taking place December 11-14, 2021 (Press release, Seagen, NOV 4, 2021, View Source [SID1234594398]). Data presentations will include updated safety and efficacy results from clinical trials examining the potential of ADCETRIS with novel combinations in patients with advanced stage classical Hodgkin lymphoma (HL), in patients with newly diagnosed CD30-expressing peripheral T-cell lymphoma (PTCL) and in patients with other histologies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We look forward to sharing new data for the continued development of ADCETRIS in combination with other therapies across patient populations," said Roger Dansey, M.D., Chief Medical Officer at Seagen. "Additionally, initial results will be presented from our SEA-BCMA program in patients with relapsed/refractory multiple myeloma."
ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL and expressed on the surface of several types of PTCL. ADCETRIS is approved in more than 75 countries for relapsed or refractory HL and systemic anaplastic large cell lymphoma (sALCL).
Presentations of Company-Sponsored ADCETRIS Trials:
Abstract Title
Abstract #
Presentation
Lead Author
The ECHELON-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma
#135
Oral presentation /
Saturday, Dec. 11,
12:00 – 1:30 p.m. EST
S. Horwitz
Classical Hodgkin Lymphoma: Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Observations of Physicians on Treatment and Interim PET-Adapted Regimens
#1390
Poster presentation /
Saturday, Dec. 11,
5:30 – 7:30 p.m. EST
S. Parsons
Classical Hodgkin Lymphoma: Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT)—a Cross-Sectional Survey of Patients with Stage III or IV Classical Hodgkin Lymphoma Compared By Age
#1966
Poster presentation /
Saturday, Dec. 11,
5:30 – 7:30 p.m. EST
D. Flora
Pharmacodynamics of SEA-BCMA, a Nonfucosylated Antibody Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma
#1197
Poster presentation /
Saturday, Dec. 11,
5:30 – 7:30 p.m. EST
D. Taft
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for advanced stage classic Hodgkin lymphoma: preliminary results from the single-arm phase 2 study (SGN35-027 Part B)
#2454
Poster presentation /
Sunday, Dec. 12,
6:00 – 8:00 p.m. EST
H. Lee
An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Overall Survival Based on the 5-Year Update from the Echelon-2 Trial in Frontline Patients with Peripheral T-Cell Lymphoma: A United States Perspective
#2440
Poster presentation /
Sunday, Dec. 12,
6:00 – 8:00 p.m. EST
T. Phillips
Classical Hodgkin Lymphoma: Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Physician First-Line Treatment Preferences for Stage III or IV Classical Hodgkin Lymphoma
#2467
Poster presentation /
Sunday, Dec. 12,
6:00 – 8:00 p.m. EST
A. Evens
An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Overall Survival Based on the 5-Year Update from the Echelon-2 Trial in Frontline Patients with Peripheral T-Cell Lymphoma: A United States Perspective
#2466
Poster presentation /
Sunday, Dec. 12,
6:00 – 8:00 p.m. EST
J. Burke
SEA-BCMA, an investigational nonfucosylated monoclonal antibody: interim results of a phase 1 study in relapsed/refractory multiple myeloma patients (SGNBCMA-001)
#2740
Poster presentation /
Sunday, Dec. 12,
6:00 – 8:00 p.m. EST
J. Hoffman
Trials-In-Progress
Brentuximab Vedotin in Combination with Nivolumab, Doxorubicin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma (SGN35-027, Trial in Progress)
#1369
Poster presentation /
Saturday, Dec. 11,
5:30 – 7:30 p.m. EST
I. Flinn
Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial in Progress)
#3564
Poster presentation /
Monday, Dec. 13,
6:00 – 8:00 p.m. EST
N. Bartlett
Frontline Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin and Prednisone in Patients With Peripheral T Cell Lymphoma With Less Than 10% CD30 Expression (SGN35 032, Trial in Progress)
#1401
Poster presentation /
Saturday, Dec. 11,
5:30 – 7:30 p.m. EST
D. Jagadeesh
Presentations of Investigator-Sponsored and Cooperative Group ADCETRIS Trials:
Abstract Title
Abstract #
Presentation
Lead Author
Brentuximab vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Expressing Peripheral T-cell Lymphomas
#133
Oral presentation /
Saturday, Dec. 11,
12:00 – 1:30 p.m. EST
A. Herrera
The Eatl-001 Trial: Results of a Phase 2 Study of Brentuximab vedotin and CHP Followed By Consolidation with High-Dose Therapy – Autologous Stem-Cell Transplantation (HDTASCT) in the Frontline Treatment of Patients with Enteropathy-Associated T-Cell Lymphoma
#136
Oral presentation /
Saturday, Dec. 11,
12:00 – 1:30 p.m. EST
D. Sibon
Interim results of a multicenter pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide, and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukemia/lymphoma
#1395
Poster presentation /
Saturday, Dec. 11,
5:30 – 7:30 p.m. EST
C. Dittus
Pacific: A Phase II Study of Brentuximab vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma
#1408
Poster presentation /
Saturday, Dec. 11,
5:30 – 7:30 p.m. EST
R. Steiner
Brentuximab vedotin plus ESHAP (BRESHAP) versus ESHAP as salvage strategy for patients with primary refractory or relapsed classical Hodgkin’s Lymphoma. Preliminary results from the BRESELIBET prospective clinical
#2459
Poster presentation /
Sunday, Dec. 12,
6:00 – 8:00 p.m. EST
A. Sureda
Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in 718 Patients with Relapsed/Refractory Hodgkin Lymphoma
#879
Oral presentation /
Monday, Dec. 13,
6:15 – 7:45 p.m. EST
J. Driessen
The Evolution of Children’s Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity
#81
Oral presentation /
Monday, Dec. 13,
6:15 – 7:45 p.m. EST
A. Lo